[The pharmacodynamics and pharmacokinetics of bonnecor in patients with different disorders of the heart rhythm].

Abstract

The clinical pharmacokinetics and the effect of bonnecor on parameters of the pharmacodynamics were studied in 53 patients with cardiac rhythm disorders, including 23 patients in the acute period of myocardial infarction. At intravenous administration of bonnecor in a dose of 0.4-0.6 mg/kg there was noted a pronounced antiarrhythmic effect with respect to both ventricular and supraventricular cardiac rhythm disorders. Bonnecor exerted no significant effect on the hemodynamic parameters. The pharmacokinetic parameters of bonnecor possess a great variability, the mean values of the parameters are close to the corresponding ones for ethacizine. Along with the unchanged drug one can detect in the blood mono-N-demethylated metabolite. The ranges of effective concentrations and those inducing side effects of the drug are given.

• Authors: L G Lozinskiĭ, I P Zamotaev, E M Zeltyn'-Abramov, V A Orlov, V L Beloborodov, E E Kosilova, M A Zalesskaia, N A Tiukavkina
• Journal: Farmakologiia i toksikologiia (Farmakol Toksikol) 1990 May-Jun Vol. 53 Issue 3 Pg. 61-3 ISSN: 0014-8318 [Print] Russia (Federation)
• Vernacular Title: Farmakodinamika i farmakokinetika bonnekora u bol'nykh s razlichnymi narusheniiami ritma serdtsa.
• PMID: 2387386 (Publication Type: Comparative Study, English Abstract, Journal Article)

Chemical References

• Anti-Arrhythmia Agents
• Dibenzazepines
• tiracizine

Topics

• Adolescent
• Adult
• Aged
• Anti-Arrhythmia Agents (pharmacokinetics, pharmacology)
• Arrhythmias, Cardiac (blood, drug therapy)
• Chromatography, High Pressure Liquid
• Dibenzazepines (pharmacokinetics, pharmacology)
• Drug Evaluation
• Electrocardiography (drug effects)
• Female
• Humans
• Male
• Middle Aged
• Myocardial Infarction (blood, drug therapy)
• Time Factors